Pyridoxine HClCAS# 58-56-0 |
- Vorinostat (SAHA, MK0683)
Catalog No.:BCC2145
CAS No.:149647-78-9
- Plumbagin
Catalog No.:BCN2586
CAS No.:481-42-5
- 360A iodide
Catalog No.:BCC1308
CAS No.:737763-37-0
- 360A
Catalog No.:BCC1307
CAS No.:794458-56-3
- AT13387
Catalog No.:BCC2122
CAS No.:912999-49-6
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 58-56-0 | SDF | Download SDF |
| PubChem ID | 6019 | Appearance | Powder |
| Formula | C8H12ClNO3 | M.Wt | 205.64 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | H2O : ≥ 50 mg/mL (243.14 mM) DMSO : ≥ 50 mg/mL (243.14 mM) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | 4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol;hydrochloride | ||
| SMILES | [H+].[Cl-].Cc1ncc(CO)c(CO)c1O | ||
| Standard InChIKey | ZUFQODAHGAHPFQ-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C8H11NO3.ClH/c1-5-8(12)7(4-11)6(3-10)2-9-5;/h2,10-12H,3-4H2,1H3;1H | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Pyridoxine HCl Dilution Calculator
Pyridoxine HCl Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 4.8629 mL | 24.3143 mL | 48.6287 mL | 97.2573 mL | 121.5717 mL |
| 5 mM | 0.9726 mL | 4.8629 mL | 9.7257 mL | 19.4515 mL | 24.3143 mL |
| 10 mM | 0.4863 mL | 2.4314 mL | 4.8629 mL | 9.7257 mL | 12.1572 mL |
| 50 mM | 0.0973 mL | 0.4863 mL | 0.9726 mL | 1.9451 mL | 2.4314 mL |
| 100 mM | 0.0486 mL | 0.2431 mL | 0.4863 mL | 0.9726 mL | 1.2157 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Pyridoxine HCl is a form of vitamin B6.
- Theophylline
Catalog No.:BCN1258
CAS No.:58-55-9
- Tetrabenazine
Catalog No.:BCC5277
CAS No.:58-46-8
- Prochlorperazine
Catalog No.:BCC3846
CAS No.:58-38-8
- Promethazine HCl
Catalog No.:BCC5480
CAS No.:58-33-3
- Desipramine hydrochloride
Catalog No.:BCC7553
CAS No.:58-28-6
- Menadione
Catalog No.:BCN8351
CAS No.:58-27-5
- Testosterone
Catalog No.:BCN2193
CAS No.:58-22-0
- Testosterone cypionate
Catalog No.:BCC9167
CAS No.:58-20-8
- Methyltestosterone
Catalog No.:BCC9045
CAS No.:58-18-4
- Aminophenazone
Catalog No.:BCC8815
CAS No.:58-15-1
- Pyrimethamine
Catalog No.:BCC2307
CAS No.:58-14-0
- Caffeine
Catalog No.:BCN5807
CAS No.:58-08-2
- Puromycin dihydrochloride
Catalog No.:BCC7860
CAS No.:58-58-2
- Puromycin aminonucleoside
Catalog No.:BCC1873
CAS No.:58-60-6
- Adenosine
Catalog No.:BCN5796
CAS No.:58-61-7
- Inosine
Catalog No.:BCN3841
CAS No.:58-63-9
- Papaverine
Catalog No.:BCC8230
CAS No.:58-74-2
- Biotin
Catalog No.:BCC3585
CAS No.:58-85-5
- D-(+)-Xylose
Catalog No.:BCN1010
CAS No.:58-86-6
- Hydrochlorothiazide
Catalog No.:BCC4786
CAS No.:58-93-5
- Chlorothiazide
Catalog No.:BCC3752
CAS No.:58-94-6
- alpha-Tocopherol acetate
Catalog No.:BCN5803
CAS No.:58-95-7
- Uridine
Catalog No.:BCN4090
CAS No.:58-96-8
- 6-Aminoquinoline
Catalog No.:BCC8766
CAS No.:580-15-4
[Effects of excess pyridoxine-HCl on growth and urinary excretion of water-soluble vitamins in weaning rats].[Pubmed:19436155]
Shokuhin Eiseigaku Zasshi. 2009 Apr;50(2):75-9.
To determine the tolerable upper intake level of pyridoxine-HCl in humans, we investigated the effects of excess pyridoxine-HCl administration on body weight gain, food intake, tissue weight, and urinary excretion of water-soluble vitamins in weaning rats. The weaning rats were freely fed ordinary diet containing 0.0007% pyridoxine-HCl (control diet) or the same diet with 0.1%, 0.5%, 0.8% or 1.0% pyridoxine-HCl for 30 days. The body weight gain in the 0.8% and 1.0% groups, and the total food intake in the 1.0% group were significantly lower than those in the control group. The urinary excretion of pantothenic acid in the pyridoxine-HCl added groups were higher than that in the control group, while excessive pyridoxine-HCl intake did not affect the urinary excretion of other water-soluble vitamins. These results showed that the no-observed-adverse-effect-level (NOAEL) for pyridoxine-HCl was 0.1% in diet, corresponding to 90 mg/kg body weight/day, and lowest-observed-adverse-effect-level (LOAEL) was 0.5% in diet, corresponding to 450 mg/kg body weight/day.
Comparative ANNs with different input layers and GA-PLS study for simultaneous spectrofluorimetric determination of melatonin and pyridoxine HCl in the presence of melatonin's main impurity.[Pubmed:23344205]
Molecules. 2013 Jan 14;18(1):974-96.
Melatonin (MLT) has many health implications, therefore it is important to develop specific analytical methods for the determination of MLT in the presence of its main impurity, N-{2-[1-({3-[2-(acetylamino)ethyl]-5-methoxy-1H-indol-2-yl}methyl)-5-methoxy-1H-i ndol-3-yl]ethyl}acetamide (DMLT) and Pyridoxine HCl (PNH) as a co-formulated drug. This work describes simple, sensitive, and reliable four multivariate calibration methods, namely artificial neural network preceded by genetic algorithm (GA-ANN), principal component analysis (PCA-ANN) and wavelet transform procedures (WT-ANN) as well as partial least squares preceded by genetic algorithm (GA-PLS) for the spectrofluorimetric determination of MLT and PNH in the presence of DMLT. Analytical performance of the proposed methods was statistically validated with respect to linearity, accuracy, precision and specificity. The proposed methods were successfully applied for the assay of MLT in laboratory prepared mixtures containing up to 15% of DMLT and in commercial MLT tablets with recoveries of no less than 99.00%. No interference was observed from common pharmaceutical additives and the results compared favorably with those obtained by a reference method.
Multidetermination of thiamine HCl and pyridoxine HCl in their mixture using continuous daubechies and biorthogonal wavelet analysis.[Pubmed:18968959]
Talanta. 2003 Mar 10;59(4):707-17.
A new graphical method based on the one-dimensional wavelet transform (WT) was proposed and tested on mixture of thiamine hydrochloride (THI) and pyridoxine hydrochloride (PYR) in the presence of strongly overlapping signals. We selected from the data of the UV-VIS absorption spectra a signal consisting of 1150 points corresponding to the concentration range 8-32 mg ml(-1) for each vitamin and we subjected it to Daubechies8 (DAUB8) and Biorthogonal6.8 (BIOR6.8) wavelet transforms. Since the peaks of the transformed signals were bigger than original ones a zero crossing method was applied to obtain the calibration graphs. In addition, the validity of Beer-Lambert law was assumed for the transformed signals. An appropriate scale setting was choosing to obtain an alternative calibration for each method. Matlab 6.5 software was used for one-dimensional wavelet analysis and the basic concepts about wavelet method were given. The obtained results were successfully compared among each other as well as with those obtained by other literature methods. The method developed in this paper is rapid, easy to apply, not expensive and it is suitable for analyzing of the overlapping signals of compounds in their mixtures without any chemical pre-treatment.
Comparing pyridoxine and doxylamine succinate-pyridoxine HCl for nausea and vomiting of pregnancy: A matched, controlled cohort study.[Pubmed:25663469]
J Clin Pharmacol. 2015 Jul;55(7):809-14.
Nausea and vomiting of pregnancy (NVP) is a common gestational condition. This is the first study to compare the use of vitamin B6 (pyridoxine) versus Diclectin (doxylamine succinate-Pyridoxine HCl) for NVP symptoms. Participants were pregnant women with NVP who used either pyridoxine or doxylamine succinate-Pyridoxine HCl for >/=4 days prior to calling the Motherisk NVP Helpline. Women receiving pyridoxine only (n = 80) were matched to a woman taking doxylamine succinate-Pyridoxine HCl only (n = 80), accounting for potential confounders and baseline level of NVP, measured by the Pregnancy Unique Quantification of Emesis (PUQE) score. Change in NVP severity after a week of therapy with either pyridoxine or doxylamine succinate-Pyridoxine HCl was quantified using the PUQE-24 scale, which describes NVP symptoms 24 hours prior to their call. Doxylamine succinate-Pyridoxine HCl use found a significant reduction in PUQE score, compared with pyridoxine (+0.5 versus -0.2, P < .05; negative denotes worsening). This association was especially prominent in women with more severe symptoms, where doxylamine succinate-Pyridoxine HCl use saw a mean improvement of 2.6 versus 0.4 with pyridoxine (P < .05). As well, doxylamine succinate-Pyridoxine HCl use was associated with fewer women experiencing moderate to severe scores after a week of treatment, compared with the pyridoxine group (7 versus 17, P < .05), despite similar baseline PUQE scores.
